Company
Instylla
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
12
510(k), De Novo and PMA
Device trials
2
As lead sponsor, any status
Adverse event reports
2
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$129M
5 Form D offerings, 2017 to 2025
Equity
$129M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $34.8M raised of $35.0M sought, first sale Jul 7, 2025, 29 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Jul 7, 2025 | Equity | $34.8M | $35.0M | 29 | Rule 506(b) | Form D/A ↗Jul 28, 20261 amendment |
| Aug 8, 2023 | Equity | $30.3M | $30.3M | 32 | Rule 506(b) | Form D/A ↗Nov 3, 20231 amendment |
| Aug 8, 2023 | Equity | $30.3M | $30.3M | 32 | Rule 506(b) | Form D ↗Nov 3, 2023 |
2 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- Instylla, Inc.
- Headquarters
- Bedford, Massachusetts
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1708696 ↗
Executives, directors and promoters
As listed on the latest Form D.
9 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Instylla.
Latest FDA decisions
The 8 newest of 12 since 2015.
- Embrace(TM) Hydrogel Embolic SystemPMA supplement
P250003-S008 · Decided Oct 23, 2026 · 178 days after receipt · Panel Track
Device type: Embolization Agent, Vascular (QVG) · Cardiology
- Verge Microcatheter510(k)
K261610 · Decided Jun 11, 2026 · 28 days after receipt
Device type: Catheter, Continuous Flush (KRA) · Cardiology
- Instylla Delivery Kit510(k)
K253769 · Decided Dec 22, 2025 · 27 days after receipt
Device type: Syringe, Piston (FMF) · Hospital Medicine & Nursing
9 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Instylla HES Hypervascular Tumor Pivotal StudyPivotal-lookingCompleted
NCT04523350 · 150 participants · Start Mar 5, 2021 · Primary completion May 1, 2024
Device: Instylla HES · For: Hypervascular Tumors
Sites: Birmingham, Alabama; Little Rock, Arkansas; Irvine, California · 15 sites in all
- (HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial BleedsActive, not recruiting
NCT05364502 · 130 participants (planned) · Start Dec 12, 2022 · Primary completion Jan 2026
Device: Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter · For: Arterial Bleeding in Solid Organs and Peripheral Arteries
Sites: Phoenix, Arizona; Long Beach, California; Stanford, California · 22 sites in all
Reports received
2
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
2
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 1 | 0 | 0 | 0 |
| Aug 26 | 1 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.